BioTech Medics, Inc., (PINKSHEETS: BTMD)
announced they are contacting various foreign government representatives
advising them of BioTech’s clinically proven SHBAN Solution which kills the
Avian Bird Flu Virus on contact as a topical solution to help prevent the
spread of the virus among humans and birds.
The clear superiority of SHBAN over other hand sanitizers is that SHBAN is
longer-lasting as it puts a non-toxic film on your hands and it does not
evaporate after application (compared to alcohol based hand sanitizers).
SHBAN is non-bleaching and has no toxic odors. Additionally, the SHBAN
3oz. size is convenient to carry in a purse, briefcase, backpack, waist
pouch or vehicle.
SHBAN can also be used in bulk to spray in poultry farms directly on the
birds, ground and cages to help kill the disease without harming the birds
(when used as directed). SHBAN has a 99% effective rate in killing the
Avian virus upon contact, compared to a 45% effective rate of a series of
drugs currently being used to inoculate birds in an attempt to protect
them.
The SHBAN(TM) solution was tested at the University of London, Queen School
of Medicine, Retroscreen Labs against the H5N1 virus. In previous in vitro
and in vivo testing SHBAN has been evaluated for its antimicrobial
properties against S. Aureus, S. Epidermidis, EC. Faecalis, E. Coli and Ps.
Aeruginosa. Tests revealed that SHBAN was extremely effective against all
species of bacteria that were tested. SHBAN has previously been tested by
Baylor Medical Center in Houston, Louisiana State University, UT Houston,
Allergan, Pathology Associates, MBA Labs and Texas A&M College of
Veterinary Medicine. SHBAN is protected under US Letters of Patent
#5,514,808, #5,574,050, #5,679,711. #5,585,391. BioTech Medics will
provide SHBAN samples to government or world health officials should they
desire to independently test the SHBAN solution.
Safe Harbor for Forward-Looking Statements.
This press contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 (the “Act”). Such
statements are subject to certain risks and uncertainties and actual
results could differ materially from those expressed in any of the
forward-looking statements. The FDA has not evaluated SHBAN and has not
expressed an opinion regarding any claims made. SHBAN is not for the
diagnosis, treatment and/or cure of any disease.
Contact:
BTMD
Investor Relations
1-800-200-2458
Information provided by: Findarticles.com
